Atara Biotherapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€162.55M - Cost of goods sold
€30.49M - Gross profit
€132.06M - SG&A expenses
€32.11M - R&D expenses
€92.52M - EBITDA
€12.33M - D&A
€3.76M - EBIT
€6.93M - Interest expenses
€3.61M - EBT
€4.96M - Tax expenses
-€28.43K - Net income
€4.99M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€74.34M - Changes in working capital
-€6.28M - Operating cash flow
-€55.07M - Capex
€77.54K - Other investing cash flow
€300.68K - Net investing cash flow
-€999.40K - Total cash dividends paid
€0.00 - Issuance of common stock
€56.78M - Debt repayment
-€372.19K - Other financing cash flow
€199.02K - Net financing cash flow
€43.52M - Foreign exchange effects
€0.00 - Net change in cash
-€12.54M - Cash at end of period
€14.56M - Free cash flow
-€54.99M
Balance sheet
- Cash and cash equivalents
€14.56M - Cash and short-term investments
€19.23M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€2.11M - Total current assets
€21.34M - Property, plant & equipment
€9.65M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€798.66K - Total non-current assets
€10.45M - Total assets
€31.79M - Accounts payable
€1.52M - Short-term debt
€0.00 - Other current liabilities
€9.64M - Total current liabilities
€12.55M - Long-term debt
€13.29M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€36.15M - Total non-current liabilities
€49.44M - Total liabilities
€61.98M - Common stock
€861.55 - Retained earnings
-€1.74B - Other equity
€0.00 - Total equity
-€30.19M - Total liabilities and shareholders' equity
€31.79M
Company information
- Market capitalization
€46.14M - Employees
153 - Enterprise Value
€73.42M
Company ratios
- Gross margin
-
81.2% Much better than peer group: -2,378,073,477,875,274,800.0% - EBITDA margin
-
7.6% Much better than peer group: -3,638,905,976,106,109,000.0% - EBIT margin
-
4.3% Much better than peer group: -3,500,662,011,173,804,000.0% - EBT margin
-
3.1% Much better than peer group: -4,138,208,319,427,697,000.0% - Net margin
-
3.1% Much better than peer group: -4,138,208,319,427,697,000.0% - ROE
-
-16.5% Much worse than peer group: 174.7% - ROA
-
15.7% Much better than peer group: -53.7% - Asset turnover
-
511.3% Much better than peer group: 16.2% - FCF margin
-
-33.9% Much better than peer group: -3,093,060,176,589,832,000.0% - FCF yield
-119.5% - Efficiency ratio
92.4% - Net sales per employee
-
€1.06M - Net income per employee
-
€32.63K